# TETRAPHASE PHARMACEUTICALS INC

TETRAPHASE PHARMACEUTICALS INC is a company headquartered in Watertown, MA, United States.

## Company overview

- **Legal name:** TETRAPHASE PHARMACEUTICALS INC
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Watertown, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001373707

## About

TETRAPHASE PHARMACEUTICALS INC is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001373707, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2020-03-12, it reported annual revenue of USD 7,376,000; net income of USD -70,085,000; total assets of USD 36,385,000 for the fiscal period ended 2019-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2019 (period ended 2019-12-31)

- **Revenue:** $7.4M (USD 7,376,000)
- **Net income:** -$70.1M (USD -70,085,000)
- **Total assets:** $36.4M (USD 36,385,000)
- **Cash and equivalents:** $21.2M (USD 21,239,000)
- **Operating cash flow:** -$63.7M (USD -63,670,000)

### FY2018 (period ended 2018-12-31)

- **Revenue:** $18.9M (USD 18,904,000)
- **Net income:** -$72.2M (USD -72,158,000)
- **Total assets:** $122.9M (USD 122,944,000)
- **Cash and equivalents:** $107.8M (USD 107,776,000)
- **Operating cash flow:** -$59.6M (USD -59,628,000)

### FY2017 (period ended 2017-12-31)

- **Revenue:** $9.7M (USD 9,666,000)
- **Net income:** -$114.8M (USD -114,752,000)
- **Total assets:** $149.0M (USD 149,040,000)
- **Cash and equivalents:** $136.4M (USD 136,411,000)

### FY2016 (period ended 2016-12-31)

- **Revenue:** $5.1M (USD 5,145,000)
- **Net income:** -$77.5M (USD -77,480,000)
- **Total assets:** $151.7M (USD 151,710,000)
- **Cash and equivalents:** $142.1M (USD 142,086,000)

## Recent SEC filings

- Form 8-K — filed 2020-07-29 — period 2020-07-28 — 8-K
- Form 8-K — filed 2020-06-24 — period 2020-06-24 — 8-K
- Form SC 13D — filed 2020-06-22 — SC 13D
- Form 8-K — filed 2020-06-22 — period 2020-06-19 — 8-K
- Form 8-K — filed 2020-06-05 — period 2020-06-04 — 8-K
- Form 8-K — filed 2020-06-04 — period 2020-06-04 — 8-K
- Form 8-K — filed 2020-06-01 — period 2020-06-01 — 8-K
- Form 8-K — filed 2020-05-29 — period 2020-05-29 — 8-K
- Form 8-K — filed 2020-05-28 — period 2020-05-27 — 8-K
- Form 8-K — filed 2020-05-27 — period 2020-05-27 — 8-K
- Form 8-K — filed 2020-05-22 — period 2020-05-21 — 8-K
- Form 8-K — filed 2020-05-21 — period 2020-05-21 — FORM 8-K

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/tetraphase-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology